Prevention of hepatic metastasis from colorectal cancer by immunotherapy after resection of colorectal cancer
- VernacularTitle:免疫治疗预防大肠癌术后肝转移
- Author:
Heping KAN
;
Fuzhou TIAN
;
Qingxian ZHOU
;
Xiaobo LIU
;
Xiaojun LI
- Publication Type:Journal Article
- From:
Chinese Journal of General Surgery
2001;10(3):234-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the preventive effect of hepatic metastasis from colorectal cancer and the immune function influence on postoperative patients with colorectal cancer treated by TIL, rIL-2 and cyclophosphamide by portal vein infusion. Methods One hundred and twenty-four patients with advanced colorectal cancer (Dukes B and Dukes C stage) were randomly divided into immunotherapy group and control group. The control group were treated with 5-Fu and MMC by intravenous injection after resection of colorectal cancer. The immunotherapy group were treated with TIL, rIL-2 and cyclophosphamide by portal vein infusion after resection of the tumor, then with chemotherapy as the control group. All cases were followed-up for 3 years. Results Eight cases (12.3%) had hepatic metastases from colorectal cancer in the immunotherapy group, but nineteen cases (33.2%) in the control group. There was significant difference between the two groups (P>0.05). The NK, IL-2 activity and CD3, CD4, CD4/CD8 levels in peripheral blood of the immunotherapy group increased significantly after treatment (P<0.05). Conclusions The TIL, rIL-2 and cyclophosphamide treatment after resection of colorectal cancer is effective in improving antitumorgenic immune function, and preventing hepatic metastases.
